Latest Nephrology news and features
Latest Urology news and features
Download our free app for iOS or Android
Researchers studied 850 testosterone-deficient men who received 1,000 mg parenteral testosterone undecanoate six weeks after baseline and then every 12 weeks for up to five years.
Hypogonadal men aged 65 years and older experience significant benefit from TRT over 12 months.
California researchers have found that low testosterone levels occur five times more often among men taking long-acting opioids.
In men taking daily opioids, duration of action, but not dose, affects risk of hypogonadism
Researchers reviewed clinical trial and postmarketing data.
Adding testosterone therapy to sildenafil is not more effective in treating erectile dysfunction (ED) than sildenafil alone,
Sildenafil plus testosterone not superior for men with erectile dysfunction, low testosterone.
Researchers predict about 1.3 million new cases of cardiovascular disease related to low testosterone over a 20-year period.
Many physicians remain wary about starting testosterone replacement therapy (TRT) in hypogonadal men in large part out of concern that it could cause progression of undiagnosed prostate cancer (PCa) or promote PCa development.
Long-term treatment found not to increase the incidence of prostate cancer.
Finding was based on a study of 1,365 men with symptomatic androgen deficiency.
Measures that led to weight loss found to raise levels significantly in overweight, prediabetic men.
Treatment is associated with weight loss and improvements in components of metabolic syndrome.
Study implicates factors other than aging, including weight gain, smoking cessation, depression and cardiovascular disease.
One case of cancer diagnosed per 212 years of testosterone replacement therapy
The FDA has approved two lower-dose formulations for Androderm, a once-daily transdermal patch for men with low testosterone.
ORLANDO, Fla.—Testosterone supplementation in elderly men with borderline low testosterone levels may not improve erectile dysfunction (ED) compared with placebo, new findings suggest.
The ratio of the second and fourth finger lengths (2D/4D ratio) may predict which men have testosterone deficiency, researchers reported.
WASHINGTON, D.C.—The FDA has approved the first and only testosterone therapy applied to the underarm.
The FDA has approved Abbott's AndroGel 1.62%, a testosterone gel that restores levels of the hormone in hypogonadal men with half the volume of gel at the starting dose than delivered in AndroGel 1%.
Low testosterone increases fat mass and visceral obesity, which is associated with insulin resistance.
A history of prostate cancer has generally been a contraindication for testosterone therapy, but the clinical model may be changing.
VIENNA—Testosterone replacement therapy benefits hypogonadal men without adversely affecting prostate safety, according to the largest international trial of hypogonadal men receiving the treatment.
Salivary testosterone (Sal-T) can be used to diagnose androgen deficiency reliably in men with end-stage renal disease (ESRD), according to a Brazilian study.
Dihydrotestosterone (DHT) treatment over two years does not halt prostate growth, according to study findings published in the Annals of Internal Medicine (2010;153:621-632).
A study of 930 men with coronary heart disease (CHD) showed that those who had testosterone deficiency were at increased risk of death.
The FDA has approved a testosterone replacement therapy gel, a colorless and odorless preparation applied with one finger to the front and inner thighs.
Endocrinologist William Rosner, MD, Professor of Medicine at Columbia University in New York, explains to Renal & Urology News what impending testosterone-testing standardization—and the current lack of it—means to urology practice and research.
Statin therapy may induce primary hypogonadism and should be considered a possible confounding factor when evaluating testosterone levels in patients with erectile dysfunction (ED), according to Italian researchers.
In elderly hypogonadal men, it can improve components of the metabolic syndrome, a study found
SAN FRANCISCO—Low serum testosterone levels may be associated with an increased risk of death from cardiovascular causes and cancer, independent of age and other risk factors, according to a recent population-based study.
TORONTO—Androgen deficiency in men aged 50 years and older may be associated with an increased risk of death, independent of adiposity and lifestyle choices, a study suggests. This association may be explained, in part, by the metabolic syndrome and elevated markers of inflammation.
